279 related articles for article (PubMed ID: 30713759)
21. Interleukin-1alpha enhances the aggressive behavior of pancreatic cancer cells by regulating the alpha6beta1-integrin and urokinase plasminogen activator receptor expression.
Sawai H; Okada Y; Funahashi H; Matsuo Y; Takahashi H; Takeyama H; Manabe T
BMC Cell Biol; 2006 Feb; 7():8. PubMed ID: 16504015
[TBL] [Abstract][Full Text] [Related]
22. Differential gene expression of urokinase-type plasminogen activator and its receptor in human renal cell carcinoma.
Bhuvarahamurthy V; Schroeder J; Kristiansen G; Roigas J; Denkert C; Johannsen M; Lein M; Loening SA; Schnorr D; Jung K; Staack A
Oncol Rep; 2005 Sep; 14(3):777-82. PubMed ID: 16077991
[TBL] [Abstract][Full Text] [Related]
23. RNA interference-directed knockdown of urokinase plasminogen activator and urokinase plasminogen activator receptor inhibits prostate cancer cell invasion, survival, and tumorigenicity in vivo.
Pulukuri SM; Gondi CS; Lakka SS; Jutla A; Estes N; Gujrati M; Rao JS
J Biol Chem; 2005 Oct; 280(43):36529-40. PubMed ID: 16127174
[TBL] [Abstract][Full Text] [Related]
24. Ascites induces modulation of alpha6beta1 integrin and urokinase plasminogen activator receptor expression and associated functions in ovarian carcinoma.
Ahmed N; Riley C; Oliva K; Rice G; Quinn M
Br J Cancer; 2005 Apr; 92(8):1475-85. PubMed ID: 15798771
[TBL] [Abstract][Full Text] [Related]
25. The receptor for urokinase-type plasminogen activator and urokinase is translocated from two distinct intracellular compartments to the plasma membrane on stimulation of human neutrophils.
Plesner T; Ploug M; Ellis V; Rønne E; Høyer-Hansen G; Wittrup M; Pedersen TL; Tscherning T; Danø K; Hansen NE
Blood; 1994 Feb; 83(3):808-15. PubMed ID: 8298141
[TBL] [Abstract][Full Text] [Related]
26. Pericellular proteolysis by leukocytes and tumor cells on substrates: focal activation and the role of urokinase-type plasminogen activator.
Kindzelskii AL; Amhad I; Keller D; Zhou MJ; Haugland RP; Garni-Wagner BA; Gyetko MR; Todd RF; Petty HR
Histochem Cell Biol; 2004 Apr; 121(4):299-310. PubMed ID: 15042374
[TBL] [Abstract][Full Text] [Related]
27. Inhibition of the tumor-associated urokinase-type plasminogen activation system: effects of high-level synthesis of soluble urokinase receptor in ovarian and breast cancer cells in vitro and in vivo.
Magdolen V; Krüger A; Sato S; Nagel J; Sperl S; Reuning U; Rettenberger P; Magdolen U; Schmitt M
Recent Results Cancer Res; 2003; 162():43-63. PubMed ID: 12790320
[TBL] [Abstract][Full Text] [Related]
28. Transforming Growth Factor-Beta and Urokinase Type Plasminogen Interplay in Cancer.
Santibanez JF; Krstic J
Curr Protein Pept Sci; 2018; 19(12):1155-1163. PubMed ID: 29086689
[TBL] [Abstract][Full Text] [Related]
29.
Rasouli BS; Ghadimi-Darsajini A; Nekouian R; Iragian GR
J Cancer Res Ther; 2017; 13(2):246-251. PubMed ID: 28643742
[TBL] [Abstract][Full Text] [Related]
30. Requirement of receptor-bound urokinase-type plasminogen activator for integrin alphavbeta5-directed cell migration.
Yebra M; Parry GC; Strömblad S; Mackman N; Rosenberg S; Mueller BM; Cheresh DA
J Biol Chem; 1996 Nov; 271(46):29393-9. PubMed ID: 8910604
[TBL] [Abstract][Full Text] [Related]
31. The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion.
Hildenbrand R; Schaaf A
Int J Oncol; 2009 Jan; 34(1):15-23. PubMed ID: 19082473
[TBL] [Abstract][Full Text] [Related]
32. Interleukin-like epithelial-to-mesenchymal transition inducer activity is controlled by proteolytic processing and plasminogen-urokinase plasminogen activator receptor system-regulated secretion during breast cancer progression.
Csiszar A; Kutay B; Wirth S; Schmidt U; Macho-Maschler S; Schreiber M; Alacakaptan M; Vogel GF; Aumayr K; Huber LA; Beug H
Breast Cancer Res; 2014 Sep; 16(5):433. PubMed ID: 25212966
[TBL] [Abstract][Full Text] [Related]
33. Urokinase plasminogen activator/urokinase-specific surface receptor expression and matrix invasion by breast cancer cells requires constitutive p38alpha mitogen-activated protein kinase activity.
Huang S; New L; Pan Z; Han J; Nemerow GR
J Biol Chem; 2000 Apr; 275(16):12266-72. PubMed ID: 10766865
[TBL] [Abstract][Full Text] [Related]
34. Differential proteome expression associated with urokinase plasminogen activator receptor (uPAR) suppression in malignant epithelial cancer.
Saldanha RG; Xu N; Molloy MP; Veal DA; Baker MS
J Proteome Res; 2008 Nov; 7(11):4792-806. PubMed ID: 18808175
[TBL] [Abstract][Full Text] [Related]
35. The urokinase-type plasminogen activator and the generation of inhibitors of urokinase activity and signaling.
Carriero MV; Stoppelli MP
Curr Pharm Des; 2011; 17(19):1944-61. PubMed ID: 21711235
[TBL] [Abstract][Full Text] [Related]
36. Urokinase-type Plasminogen Activator (uPA) Binding to the uPA Receptor (uPAR) Promotes Axonal Regeneration in the Central Nervous System.
Merino P; Diaz A; Jeanneret V; Wu F; Torre E; Cheng L; Yepes M
J Biol Chem; 2017 Feb; 292(7):2741-2753. PubMed ID: 27986809
[TBL] [Abstract][Full Text] [Related]
37. The urokinase plasminogen activator and its receptor: role in cell growth and apoptosis.
Alfano D; Franco P; Vocca I; Gambi N; Pisa V; Mancini A; Caputi M; Carriero MV; Iaccarino I; Stoppelli MP
Thromb Haemost; 2005 Feb; 93(2):205-11. PubMed ID: 15711734
[TBL] [Abstract][Full Text] [Related]
38. Dynamic assembly of the urokinase-type plasminogen activator signaling receptor complex determines the mitogenic activity of urokinase-type plasminogen activator.
Jo M; Thomas KS; Marozkina N; Amin TJ; Silva CM; Parsons SJ; Gonias SL
J Biol Chem; 2005 Apr; 280(17):17449-57. PubMed ID: 15728176
[TBL] [Abstract][Full Text] [Related]
39. Binding of human urokinase-type plasminogen activator to its receptor: residues involved in species specificity and binding.
Quax PH; Grimbergen JM; Lansink M; Bakker AH; Blatter MC; Belin D; van Hinsbergh VW; Verheijen JH
Arterioscler Thromb Vasc Biol; 1998 May; 18(5):693-701. PubMed ID: 9598826
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]